Gynecological malignancies and hormonal therapies: Clinical management and recommendations

Table 2 Endometrial cancer

Ref.	Study design	HRT vs control	Stage	Type of HRT	Months HRT	Months follow up	Recurrence HRT vs controls	Study conclusions
Creasman et al[58]	Retrospective case-control	47/174	1	Oral/Vaginal/Oral + Vaginal Estrogen	Mean 32	25-150	2 vs 15	Estrogen has a good effect on DFS an OS
Lee et al[59]	Case-control	44/99	1	Oral Estrogen	Median 64	24-84	0 vs 8	Estrogen are safe in low risk patients
Bryant[60]	Retrospective cohort	20	1-2	Conjugated Estrogen ± Depo Provera	12-132	42-168	NS	No recurrences in patients treated with HRT
Baker[61]	Retrospective cohort	31	NS	Oral/Vaginal/transdermal Estrogen		192	NS	No increase of recurrence or mortality in HRT users
Chapman et al[62]	Retrospective case-control	62/61	1-2	Oral/Vaginal Estrogen ± MPA 2.5 mg	Mean 49.1	Median 57.1	2 vs 8	No decreased DFI or increased recurrence in users vs non users in early stage
Suriano et al[63]	Retrospective cohort with matched controls	75/75	1-3	Oral Estrogen ± MPA 2.5 mg	Mean 83	Mean 83	2 vs 11	HRT ± Progestogen do not increate recurrence rate
Barakat et al[64]	Randomised double blind trial	618 vs 618	1-2	Oral Estrogen	Planned 36	Median 35.7	14 vs 12	Not completed. Low recurrence rate
Ayhan et al[65]	Prospective case-control	50/52	1-2	Conjugated Estrogen + Progesteron	Mean 49.1	Mean 49.1	0 vs 1	Postoperative HRT did not increase recurrence or death rate

HRT: Hormone replacement therapy; MPA: Medroxyprogesterone acetate; DFS: Disease free survival; OS: Overall survival; DFI: Disease free interval; NS: Not specified.